AU2018230429B2 - Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors - Google Patents

Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors Download PDF

Info

Publication number
AU2018230429B2
AU2018230429B2 AU2018230429A AU2018230429A AU2018230429B2 AU 2018230429 B2 AU2018230429 B2 AU 2018230429B2 AU 2018230429 A AU2018230429 A AU 2018230429A AU 2018230429 A AU2018230429 A AU 2018230429A AU 2018230429 B2 AU2018230429 B2 AU 2018230429B2
Authority
AU
Australia
Prior art keywords
catecholamine
patient
gra
treatment
glucocorticoid receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018230429A
Other languages
English (en)
Other versions
AU2018230429A1 (en
Inventor
Andreas G. MORAITIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corcept Therapeutics Inc
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of AU2018230429A1 publication Critical patent/AU2018230429A1/en
Application granted granted Critical
Publication of AU2018230429B2 publication Critical patent/AU2018230429B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
AU2018230429A 2017-03-09 2018-03-08 Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors Active AU2018230429B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762469296P 2017-03-09 2017-03-09
US62/469,296 2017-03-09
PCT/US2018/021592 WO2018165460A1 (en) 2017-03-09 2018-03-08 Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors

Publications (2)

Publication Number Publication Date
AU2018230429A1 AU2018230429A1 (en) 2019-09-05
AU2018230429B2 true AU2018230429B2 (en) 2023-06-15

Family

ID=63446773

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018230429A Active AU2018230429B2 (en) 2017-03-09 2018-03-08 Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors

Country Status (8)

Country Link
US (1) US11045482B2 (cg-RX-API-DMAC7.html)
EP (1) EP3592358A4 (cg-RX-API-DMAC7.html)
JP (4) JP7564620B2 (cg-RX-API-DMAC7.html)
CN (1) CN110475558A (cg-RX-API-DMAC7.html)
AU (1) AU2018230429B2 (cg-RX-API-DMAC7.html)
CA (1) CA3053806A1 (cg-RX-API-DMAC7.html)
MX (1) MX2019010732A (cg-RX-API-DMAC7.html)
WO (1) WO2018165460A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021007402A (es) 2018-12-20 2021-07-15 Corcept Therapeutics Inc Metodos para la toma de imagenes y el tratamiento de tumores positivos para el receptor de somatostatina.
JP2021079146A (ja) * 2021-02-22 2021-05-27 株式会社三洋物産 遊技機
JP7315071B2 (ja) * 2021-03-03 2023-07-26 株式会社三洋物産 遊技機

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009050136A2 (en) * 2007-10-17 2009-04-23 Laboratoire Hra Pharma Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome
WO2013039916A1 (en) * 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
WO2016140867A1 (en) * 2015-03-02 2016-09-09 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonist and somatostatin analogues to treat acth-secreting tumors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606736D0 (en) 1996-02-19 1996-06-05 Shire International Licensing Therapeutic method
CA2246791A1 (en) 1998-09-01 2000-03-01 Alison Buchan Treatment of endothelium with somatostatin analogues
US6818739B2 (en) 1999-12-03 2004-11-16 Ndsu Research Foundation Somatostatins
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
JP2004525135A (ja) 2001-03-23 2004-08-19 コーセプト セラピューティクス, インコーポレイテッド 糖質コルチコイドレセプター特異的アンタゴニストを使用するストレス障害を処置するための方法
WO2003057214A1 (en) 2001-12-28 2003-07-17 Somatocor Pharmaceuticals, Inc. Imidazolidin-2,4-dione derivatives as non-peptide somatostatin receptor ligands
RU28362U1 (ru) 2002-12-10 2003-03-20 Закрытое акционерное общество "Дальневосточная технология" Лист заходной футеровки
JP4931794B2 (ja) 2004-03-09 2012-05-16 コーセプト セラピューティクス, インコーポレイテッド 縮合環アザデカリン糖質コルチコイド受容体モジュレーター
GB0428151D0 (en) * 2004-12-22 2005-01-26 Novartis Ag Organic compounds
EP2145186A4 (en) * 2007-05-15 2010-10-20 Water Technologies Corp DEVICE AND METHOD FOR THE DETECTION OF METANEPHRINES IN PLASMA
ES2351569B8 (es) 2009-05-07 2012-06-20 Bcn Peptides S.A. Ligandos peptídicos de receptores de somatostatina.
AU2010247766B2 (en) 2009-05-12 2015-05-21 Corcept Therapeutics, Inc. Solid forms and process for preparing
WO2011094814A1 (en) * 2010-02-05 2011-08-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
CN103596431B (zh) 2011-03-18 2016-06-22 科赛普特治疗公司 嘧啶环己基糖皮质激素受体调节剂
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
ES2943542T3 (es) 2013-11-25 2023-06-14 Corcept Therapeutics Inc Moduladores del receptor de glucocorticoides de azadecalina condensada con octahidro
US9943526B2 (en) * 2015-04-21 2018-04-17 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patients

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009050136A2 (en) * 2007-10-17 2009-04-23 Laboratoire Hra Pharma Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome
WO2013039916A1 (en) * 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
WO2016140867A1 (en) * 2015-03-02 2016-09-09 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonist and somatostatin analogues to treat acth-secreting tumors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DE BRUIN, C. et al. The Journal of Clinical Endocrinology & Metabolism (2012) Vol.97 Issue 2, pages 455 to 462 *
SARTOR O; CUTLER JR G B: "Mifepristone: Treatment of Cushing's syndrome", CLINICAL OBSTETRICS AND GYNECOLOGY., HARPER AND ROW, HAGERSTOWN, MD., US, vol. 39, no. 2, 1 January 1996 (1996-01-01), US , pages 506 - 510, XP009184753, ISSN: 0009-9201, DOI: 10.1097/00003081-199606000-00024 *

Also Published As

Publication number Publication date
CN110475558A (zh) 2019-11-19
US20180256604A1 (en) 2018-09-13
CA3053806A1 (en) 2018-09-13
JP7564620B2 (ja) 2024-10-09
JP2024074854A (ja) 2024-05-31
WO2018165460A1 (en) 2018-09-13
EP3592358A1 (en) 2020-01-15
JP2020510011A (ja) 2020-04-02
EP3592358A4 (en) 2020-12-16
US11045482B2 (en) 2021-06-29
JP2022090003A (ja) 2022-06-16
JP2026099911A (ja) 2026-06-18
MX2019010732A (es) 2019-11-01
AU2018230429A1 (en) 2019-09-05

Similar Documents

Publication Publication Date Title
US11073523B2 (en) Method for differentially diagnosing ACTH-dependent Cushing's syndrome
CA3034114C (en) Glucocorticoid receptor modulators to treat pancreatic cancer
CA2977591C (en) USE OF A GLUCOCORTICOID RECEPTOR ANTAGONIST AND SOMATOSTATIN ANALOGUES FOR THE TREATMENT OF ADRENOCORTICOTROPIC HORMONE (ACTH) SECRETIVING TUMORS
JP2024074854A (ja) カテコールアミン分泌腫瘍の処置における糖質コルチイド受容体モジレータの使用
BR112021015129A2 (pt) Método para tratar um paciente que sofre de hipercortisolemia e um sintoma ou comorbidade da mesma
CA2978960C (en) Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
JP2022164775A (ja) 選択的グルココルチコイドレセプターモジュレーターを使用して神経上皮腫瘍を処置する方法
JP2023052618A (ja) 糖質コルチコイド受容体モジュレータおよびcyp3aインヒビタの併用投与
RU2663455C2 (ru) КОМБИНАЦИЯ АНАЛОГОВ СОМАТОСТАТИНА С ИНГИБИТОРАМИ 11β- ГИДРОКСИЛАЗЫ
WO2009021022A2 (en) Modulating the activity of nuclear receptors in order to treat hypoxia-related disorders
WO2024050342A1 (en) Methods of treating prostate cancer using exicorilant and enzalutamide
HK1255714B (en) Method for differentially diagnosing acth-dependent cushing's syndrome

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)